Committed Investment : July 2025
Status : Active Portfolio Company
More than 10 million people die each year from late-stage, or metastatic, cancer. Metastatic cancer is not one disease, but many diseases that each respond differently to treatment, making it very challenging to manage. AIQ has a novel technology to help oncologists optimize therapy for patients with late-stage cancer. The technology analyzes existing, standard-of-care imaging data but is not a radiology or diagnostic tool. Rather, AIQ provides its analysis directly to the oncologist, who uses it to make earlier and more accurate therapy adjustments. Oncologists cannot get this information from any other source. AIQ markets its technology to hospital systems as a technology-enabled service.
